Question 1

Does UBS Group own SAVA stock?

Accepted Answer

Yes. As of its Q2 2026 13F, UBS Group holds 39,062 shares of SAVA (Filana Therapeutics), worth $46,484.

Question 2

How many shares of SAVA does UBS Group own?

Accepted Answer

As of its Q2 2026 13F, UBS Group holds 39,062 shares of SAVA (Filana Therapeutics).

Question 3

What is UBS Group's SAVA position worth?

Accepted Answer

As of its Q2 2026 13F, UBS Group's SAVA position is worth $46,484.

Question 4

Is UBS Group buying or selling SAVA?

Accepted Answer

In Q2 2026, UBS Group increased its SAVA position from 11,603 to 39,062 shares.

Question 5

When did UBS Group first buy SAVA?

Accepted Answer

UBS Group already held SAVA in its Q1 2019 13F, the earliest on record, and has listed it in 30 quarterly 13F filings.

Quarter	Action	Shares	Change	Value	Weight	Price	Conviction
2026-Q2 Latest	Increased	39,062	+236.7%	$46,484	0.0%	$1.19	22
2026-Q1	Decreased	11,603	-61.1%	$19,609	0.0%	$1.69	0
2025-Q4	Decreased	29,869	-84.2%	$59,140	0.0%	$1.98	0
2025-Q3	Decreased	188,993	-0.6%	$549,970	0.0%	$2.91	0
2025-Q2	Decreased	190,085	-65.2%	$344,054	0.0%	$1.81	0
2025-Q1	Decreased	545,815	-41.4%	$818,723	0.0%	$1.50	0
2024-Q4	Increased	930,726	+947.3%	$2.2M	0.0%	$2.36	42
2024-Q3	Increased	88,873	+41.0%	$2.6M	0.0%	$29.43	35